Physician profile
Katherine Mackenzie
NPI 1083106421
$435.07
in general payments reported to CMS, 2019-2025
15 companies · $80.36 in 2025
The $80.36 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $31.10 · 2020: $69.91 · 2021: $140 · 2022: $67.42 · 2024: $46.38 · 2025: $80.36.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $127.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $126.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $126.72 | 2020-2021 | |
| Amgen INC. | $33.04 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $32.42 | 2024-2025 | Austedo Xr, Uzedy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.10 | 2019 | |
| Merck Sharp & Dohme LLC | $31.09 | 2021-2022 | |
| Alexion Pharmaceuticals, INC. | $26.65 | 2021 | |
| Abbott Laboratories | $23.82 | 2025 | Freestyle Libre 3 |
| Abbvie INC. | $21.69 | 2022 | |
| Exact Sciences Corporation | $20.81 | 2025 | The Cologuard Plus Collection Kit |
| Dynavax Technologies Corporation | $19.56 | 2025 | Heplisav-B |
| Philips North America LLC | $16.52 | 2024 | (Ck7) Extended Holter |
| Lilly USA, LLC | $14.03 | 2020 | |
| Glaxosmithkline, LLC. | $13.61 | 2024 | Shingrix, Arexvy |
| Novo Nordisk INC | $12.20 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $11.81 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katherine Mackenzie listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.